
VANI Stock Forecast & Price Target
VANI Analyst Ratings
Bulls say
Vivani Medical is positioned for potential growth due to the promising development of NPM-139, which has shown the ability to enhance the safety and tolerability of current treatments for chronic conditions, specifically targeting semaglutide therapies. The positive data indicating an approximate 20% weight loss sustained over six months suggests strong efficacy, which could enhance patient compliance and reduce therapy discontinuation rates. Furthermore, the advancements towards clinical development are supported by encouraging results, bolstering the company's prospects within both its Biopharm and Neuromodulation Divisions.
Bears say
Vivani Medical Inc faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential failure of its lead candidate, NPM-139, in clinical trials. There are also concerns regarding NPM-139's ability to secure necessary regulatory approval and achieve commercial success, given uncertainties related to market size, penetration rates, and competition in the biopharmaceutical sector. Additionally, the company is exposed to dilution risk, which could further impact investor confidence and financial stability.
This aggregate rating is based on analysts' research of Vivani Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
VANI Analyst Forecast & Price Prediction
Start investing in VANI
Order type
Buy in
Order amount
Est. shares
0 shares